Regeneron Pharmaceuticals' Invested Capital rose 5.56% to $31.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 billion, marking a year-over-year increase of 5.56%. This contributed to the annual value of $30.1 billion for FY2024, which is 7.57% up from last year.
Regeneron Pharmaceuticals' Invested Capital amounted to $31.0 billion in Q3 2025, which was up 3.40% from $29.9 billion recorded in Q2 2025.
Regeneron Pharmaceuticals' 5-year Invested Capital high stood at $31.0 billion for Q3 2025, and its period low was $14.0 billion during Q1 2021.
Over the past 3 years, Regeneron Pharmaceuticals' median Invested Capital value was $28.2 billion (recorded in 2024), while the average stood at $27.8 billion.
Data for Regeneron Pharmaceuticals' Invested Capital shows a peak YoY soared of 89.99% (in 2021) over the last 5 years.
Regeneron Pharmaceuticals' Invested Capital (Quarterly) stood at $20.7 billion in 2021, then rose by 18.78% to $24.6 billion in 2022, then rose by 13.43% to $28.0 billion in 2023, then grew by 7.57% to $30.1 billion in 2024, then rose by 5.56% to $31.0 billion in 2025.
Its Invested Capital stands at $31.0 billion for Q3 2025, versus $29.9 billion for Q2 2025 and $29.4 billion for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value